Weight loss was never the whole story. The largest cardiovascular outcomes trial in this drug class found semaglutide cuts heart attacks and strokes — in people who don't have diabetes at all.
Semaglutide and tirzepatide were approved on the strength of weight-loss data. But obesity's real danger isn't the number on the scale — it's the downstream risk of heart attack, stroke, and cardiovascular death. Whether a weight-loss drug actually lowers that risk is a separate question, and it took a dedicated, multi-year outcomes trial to answer it.
That trial is SELECT (Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity), and it's the reason semaglutide's story shifted from "weight-loss drug" to "cardioprotective drug" in a lot of clinicians' minds.
SELECT enrolled people who already had established cardiovascular disease and a BMI of 27 or higher, but explicitly excluded anyone with diabetes — isolating the drug's effect on heart risk from its glucose-lowering effect.
This is what's called an "event-driven" trial — it ran until enough cardiovascular events had accumulated across both arms to statistically compare them, rather than stopping at a fixed calendar date.
Semaglutide reduced the combined rate of cardiovascular death, heart attack, or stroke by 20% versus placebo — 6.5% of the semaglutide group had an event versus 8.0% on placebo. A prespecified follow-up analysis found roughly a third of that benefit tracked with waist-circumference reduction — meaning most of the protective effect wasn't explained by weight loss alone.
Sources: Lincoff et al., NEJM 2023, "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes" (SELECT trial) · NEJM.org · adiposity-mediation follow-up analysis via ScienceDirect.
This result doesn't apply to everyone on a GLP-1. SELECT specifically studied people with obesity or overweight who already had cardiovascular disease and no diabetes. If that's not your situation, the trial doesn't tell you how much cardiovascular benefit — if any — to expect. It's still a meaningful data point about what this drug class can do beyond weight loss.
The benefit built up over years of continuous dosing, not weeks. Participants were followed for an average of over three years on a weekly injection schedule. Cardiovascular protection in trials like this reflects sustained, consistent exposure to the drug — not an occasional dose.
GLP1ShotDay exists for exactly that reason: staying on schedule week after week is the part of GLP-1 therapy that's easy to let slip, and it's also the part the long-term outcome data is actually measuring.
This article summarizes findings from a published, peer-reviewed clinical trial for general education. It is not medical advice, does not indicate your individual cardiovascular risk or benefit, and does not replace guidance from your prescriber or cardiologist.